Last checked at 17 Nov 2009 07:00
Deltex Medical Group plc
NHS Trust wins award for implementation of ODM
17 November 2009 - Deltex Medical Group plc ("Deltex Medical" "Company" or "Group"), the global leader in oesophageal Doppler monitoring ("ODM"), today announces that a major NHS hospital Trust has won an award for its project to implement the Company's ODM products.
Central Manchester University Hospitals NHS Foundation Trust won Northwest Biomedical's 2009 'Healthcare Project of the Year' Award' for its 'The Oesophageal Doppler guided intraoperative fluid management in major surgery' project.
This award relates to the project at Manchester Royal Infirmary to implement ODM as one of three NHS hospitals participating in the NHS National Technology Adoption Centre's (NTAC) project on the implementation of ODM. The award was sponsored by Trustech, the North West NHS Innovation Hub. Details of the project are expected to be published in NTAC's forthcoming 'How to, Why to' guide to ODM adoption in the NHS.
Ewan Phillips, Deltex Medical's chief executive, commented:
"We are delighted that the Manchester Royal Infirmary's project to implement our ODM products in major surgery has won Northwest Biomedical's Healthcare Project of the Year Award. Recognition of successful innovation from within the NHS system is a further key step towards achieving our goal of system-wide adoption of ODM."
For further information, please contact:-
Deltex Medical Group plc 01243 774 837
Nigel Keen, Chairman njk@deltexmedical.com
Ewan Phillips, Chief Executive eap@deltexmedical.com
Paul Mitchell, Finance Director pjm@deltexmedical.com
Nominated Adviser & Broker
Arden Partners plc 020 7398 1600
Chris Hardie chris.hardie@arden-partners.com
Matthew Armitt matthew.armitt@arden-partners.com
Kreab Gavin Anderson 020 7554 1400
Deborah Walter dwalter@kreabgavinanderson.com
Robert Speed rspeed@kreabgavinanderson.com
Notes for Editors
Deltex Medical manufactures and markets the CardioQ-ODM™ monitor, which uses disposable ultra-sound probes inserted into the oesophagus to determine the amount of blood being pumped around the body - 'circulating blood volume'. Reduced circulating blood volume is known as hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications including peripheral and major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every patient having surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma from the surgery itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the amount of circulating blood significantly reduces post-operative complications allowing patients to make a faster, more complete recovery and return home earlier.
The CardioQ-ODM incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the CardioQ-ODM provides clinicians with the ability to haemodynamically optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been scientifically proven to improve the speed and quality of patient recovery and reduce hospital stay.
There are already over 1,750 CardioQ-ODMs currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. In addition, there are currently more than 200 clinical publications on the use of the CardioQ-ODM which have repeatedly:-
The SupraQ™ is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ-ODM in a similar format and is used for taking snapshots or monitoring over short periods.